TriSalus Life Sciences, Inc. (TLSI)
4.985
-0.16
(-3.02%)
USD |
NASDAQ |
Sep 03, 16:00
4.985
0.00 (0.00%)
After-Hours: 20:00
TriSalus Life Sciences Shareholders Equity (Quarterly) : 6.55M for June 30, 2026
Shareholders Equity (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Shareholders Equity (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 6.55M |
| March 31, 2026 | 12.81M |
| December 31, 2025 | -33.86M |
| September 30, 2025 | -26.72M |
| June 30, 2025 | -19.42M |
| March 31, 2025 | -34.37M |
| December 31, 2024 | -25.89M |
| September 30, 2024 | -20.43M |
| June 30, 2024 | -24.15M |
| March 31, 2024 | -34.92M |
| December 31, 2023 | -27.06M |
| September 30, 2023 | 8.487M |
| Date | Value |
|---|---|
| June 30, 2023 | -3.074M |
| March 31, 2023 | 6.31M |
| December 31, 2022 | -12.32M |
| September 30, 2022 | 239.17M |
| June 30, 2022 | 238.51M |
| March 31, 2022 | 236.12M |
| December 31, 2021 | 233.28M |
| September 30, 2021 | 230.39M |
| June 30, 2021 | 228.52M |
| March 31, 2021 | 228.14M |
| December 31, 2020 | |
| September 30, 2020 | 0.024M |
Shareholders' Equity Definition
Represents the value of Shareholders' Equity as of the close of the report date, belonging to both Preferred and Common Equity Shareholders.
Shareholders Equity (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Shareholders Equity (Quarterly) Benchmarks
| ACADIA Pharmaceuticals, Inc. | 1.307B |
| Alnylam Pharmaceuticals, Inc. | 1.354B |
| Anika Therapeutics, Inc. | 137.28M |
| Savara, Inc. | 143.66M |
| Vericel Corp. | 370.04M |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 62.45M |
| Total Liabilities (Quarterly) | 55.90M |
| Debt to Equity Ratio | 5.256 |
| Current Ratio | 5.348 |
| Net Debt Paydown Yield | -0.09% |